AU4709593A - Use of inhibitors of vacuolar-type H+ atpases - Google Patents

Use of inhibitors of vacuolar-type H+ atpases

Info

Publication number
AU4709593A
AU4709593A AU47095/93A AU4709593A AU4709593A AU 4709593 A AU4709593 A AU 4709593A AU 47095/93 A AU47095/93 A AU 47095/93A AU 4709593 A AU4709593 A AU 4709593A AU 4709593 A AU4709593 A AU 4709593A
Authority
AU
Australia
Prior art keywords
atpases
vacuolar
inhibitors
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU47095/93A
Inventor
Massimo Bugnoli
Cesare Montecucco
Emanuele Papini
Rino Rappuoli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GSK Vaccines SRL
Original Assignee
Biocine Sclavo SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocine Sclavo SpA filed Critical Biocine Sclavo SpA
Publication of AU4709593A publication Critical patent/AU4709593A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU47095/93A 1992-08-12 1993-08-11 Use of inhibitors of vacuolar-type H+ atpases Abandoned AU4709593A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITFI9200167 1992-08-12
ITFI920167A IT1258182B (en) 1992-08-12 1992-08-12 COMPOSITIONS CONTAINING BAFILOMYCINA FOR THE VACUOLIZATION INHIBITION INDUCED BY HELICOBACTER PYLORI
PCT/EP1993/002149 WO1994004161A1 (en) 1992-08-12 1993-08-11 Use of inhibitors of vacuolar-type h+ atpases

Publications (1)

Publication Number Publication Date
AU4709593A true AU4709593A (en) 1994-03-15

Family

ID=11350200

Family Applications (1)

Application Number Title Priority Date Filing Date
AU47095/93A Abandoned AU4709593A (en) 1992-08-12 1993-08-11 Use of inhibitors of vacuolar-type H+ atpases

Country Status (6)

Country Link
EP (1) EP0654999A1 (en)
JP (1) JPH08502725A (en)
AU (1) AU4709593A (en)
CA (1) CA2142313A1 (en)
IT (1) IT1258182B (en)
WO (1) WO1994004161A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721349A (en) * 1992-02-26 1998-02-24 Vanderbilt University Vacuolating toxin-deficient H. pylori
AU3728293A (en) * 1992-02-26 1993-09-13 Vanderbilt University Purified vacuolating toxin from (helicobacter) pylori and methods to use same
US5859219A (en) * 1992-02-26 1999-01-12 Vanderbilt University Purified vacuolating toxin from Helicobacter pylori and methods to use same
AU4259096A (en) * 1994-12-02 1996-06-19 Byk Gulden Lomberg Chemische Fabrik Gmbh Screening model
DE4442970A1 (en) * 1994-12-02 1996-06-05 Byk Gulden Lomberg Chem Fab Model for screening cpds. for inhibition of Helicobacter
WO2012045451A1 (en) 2010-10-05 2012-04-12 Ludwig-Maximilians-Universitaet Muenchen Novel therapeutic treatment of progranulin-dependent diseases
US20220105076A1 (en) * 2019-01-18 2022-04-07 Japan Science And Technology Agency Inhibitor for V-Atpase Activity, Antibacterial Agent, Medicine, Antibacterial Method and Screening Method

Also Published As

Publication number Publication date
CA2142313A1 (en) 1994-03-03
WO1994004161A1 (en) 1994-03-03
EP0654999A1 (en) 1995-05-31
ITFI920167A1 (en) 1994-02-12
ITFI920167A0 (en) 1992-08-12
IT1258182B (en) 1996-02-20
JPH08502725A (en) 1996-03-26

Similar Documents

Publication Publication Date Title
AU4267293A (en) Use of MMP inhibitors
AU4873193A (en) Use of substituted benzimidazoles
AU1002192A (en) Combined method of determining fires
AU4251993A (en) Substituted 4-aza-5A-androstan-ones as 5A-reductase inhibitors
HUP9801877A3 (en) Medicaments containing tetrahydrofuryl-sulphonamide-derivative as inhibitors of aspartyl-proteases
AU4953793A (en) Multicistronic expression units and their use
AU4013193A (en) Method of maintaining relationships between elements
AU5533094A (en) Enzyme inhibitors
PL327569A1 (en) Promedications of thrombosin inhibitors
AU7294194A (en) Substituted heterocyclylisoquinolinium salts and compositions and method of use thereof
AU4028995A (en) Antitumor compositions and methods of treatment
AU5218593A (en) Method of milling
AU635415B2 (en) Use of n-alkyl-lactams as crystallization inhibitors
AU4772493A (en) Sulfo-derivatives of adenosine
AU4868493A (en) Method of combining polymers
GB9320785D0 (en) Dibenzylheterocyclic or dibenzylcycloalkyl derivatives as inhibitors of hiv intergrase
AU5323694A (en) 17beta -carboxanilides of 4-aza-5alpha-androstan-3-ones as 5alpha-reductase inhibitors
AU5184393A (en) Substituted derivatives of diaminophthalimide
AU4709593A (en) Use of inhibitors of vacuolar-type H+ atpases
AU6723294A (en) Use of simmondsine
AU4220193A (en) Deazaaminopterins for treatment of inflammation
AU5001793A (en) Method of decreasing cutaneous senescence
AU4532893A (en) Antihypercholesterolemic compounds and related pharmaceutical compositions and methods of use
AU5371694A (en) Use of the tarchonanthus camphoratus
AU7286694A (en) Cessation of tobacco use